JP2019510001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510001A5 JP2019510001A5 JP2018544185A JP2018544185A JP2019510001A5 JP 2019510001 A5 JP2019510001 A5 JP 2019510001A5 JP 2018544185 A JP2018544185 A JP 2018544185A JP 2018544185 A JP2018544185 A JP 2018544185A JP 2019510001 A5 JP2019510001 A5 JP 2019510001A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- use according
- item
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022023843A JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298366P | 2016-02-22 | 2016-02-22 | |
| US62/298,366 | 2016-02-22 | ||
| PCT/US2017/018938 WO2017147182A1 (en) | 2016-02-22 | 2017-02-22 | Actrii antagonists for use in increasing immune activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023843A Division JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510001A JP2019510001A (ja) | 2019-04-11 |
| JP2019510001A5 true JP2019510001A5 (enExample) | 2020-04-09 |
| JP7058606B2 JP7058606B2 (ja) | 2022-04-22 |
Family
ID=59629767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544185A Expired - Fee Related JP7058606B2 (ja) | 2016-02-22 | 2017-02-22 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
| JP2022023843A Pending JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023843A Pending JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20170240639A1 (enExample) |
| EP (1) | EP3420002A4 (enExample) |
| JP (2) | JP7058606B2 (enExample) |
| KR (1) | KR20180128405A (enExample) |
| CN (1) | CN109311998A (enExample) |
| AU (1) | AU2017222526A1 (enExample) |
| CA (1) | CA3014197A1 (enExample) |
| WO (1) | WO2017147182A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| CN110678195A (zh) | 2016-10-05 | 2020-01-10 | 阿塞勒隆制药公司 | ALK4:ActRIIB异多聚体及其用途 |
| CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| WO2018144542A1 (en) * | 2017-02-01 | 2018-08-09 | Acceleron Pharma Inc. | TGFβ AND ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN108129572B (zh) * | 2018-01-04 | 2021-01-29 | 河南大学 | 人GDF11-Fc融合蛋白在治疗溃疡性结肠炎中的应用 |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| IL278546B2 (en) | 2018-05-09 | 2026-03-01 | Keros Therapeutics Inc | Activin receptor type IIA variants and methods of using them |
| US20220089683A1 (en) * | 2018-06-15 | 2022-03-24 | Acceleron Pharma Inc. | Bi-and tri-functional fusion proteins and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CA3142149A1 (en) | 2019-05-30 | 2020-12-03 | Acceleron Pharma, Inc. | Actrii-binding proteins and uses thereof |
| KR20220054608A (ko) | 2019-09-03 | 2022-05-03 | 노파르티스 아게 | ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제 |
| WO2021072302A1 (en) * | 2019-10-10 | 2021-04-15 | New York Stem Cell Foundation, Inc. | Modified stem cells and methods of use thereof |
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CN119529092A (zh) * | 2021-09-03 | 2025-02-28 | 来凯医药科技(上海)有限公司 | 抗acvr2a抗体及其用途 |
| CN122404555A (zh) * | 2025-01-17 | 2026-07-17 | 沈阳三生制药有限责任公司 | 结合acvr2a和/或acvr2b的抗体及其制备与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI584815B (zh) * | 2007-02-01 | 2017-06-01 | 艾瑟勒朗法瑪公司 | 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途 |
| KR102170682B1 (ko) * | 2009-08-13 | 2020-10-28 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| EP3202459B1 (en) * | 2009-09-09 | 2021-04-14 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| KR101461706B1 (ko) * | 2011-04-04 | 2014-11-18 | 한국생명공학연구원 | Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제 |
| WO2013063536A1 (en) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| GR1007832B (el) * | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| JP2015525230A (ja) * | 2012-06-11 | 2015-09-03 | アムジエン・インコーポレーテツド | デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用 |
| WO2014172448A2 (en) * | 2013-04-17 | 2014-10-23 | Anaptysbio, Inc. | Antibodies directed against activin receptor type ii (actrii) |
| PE20170471A1 (es) * | 2014-06-13 | 2017-05-14 | Santa Maria Biotherapeutics Inc | Polipeptidos receptores formulados y metodos relacionados |
| WO2016090035A2 (en) * | 2014-12-02 | 2016-06-09 | La Jolla Institute For Allergy And Immunology | Modulators of activin and methods for modulating immune responses and t follicular helper cells |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
-
2017
- 2017-02-22 KR KR1020187027012A patent/KR20180128405A/ko not_active Abandoned
- 2017-02-22 JP JP2018544185A patent/JP7058606B2/ja not_active Expired - Fee Related
- 2017-02-22 EP EP17757142.9A patent/EP3420002A4/en active Pending
- 2017-02-22 WO PCT/US2017/018938 patent/WO2017147182A1/en not_active Ceased
- 2017-02-22 CN CN201780024969.4A patent/CN109311998A/zh active Pending
- 2017-02-22 US US15/439,386 patent/US20170240639A1/en not_active Abandoned
- 2017-02-22 AU AU2017222526A patent/AU2017222526A1/en not_active Abandoned
- 2017-02-22 CA CA3014197A patent/CA3014197A1/en active Pending
-
2022
- 2022-02-18 JP JP2022023843A patent/JP2022062277A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | cGAS-STING, an important pathway in cancer immunotherapy | |
| Elster et al. | HER2-family signalling mechanisms, clinical implications and targeting in breast cancer | |
| Duffy et al. | Immunological off-target effects of standard treatments in gastrointestinal cancers | |
| Arora et al. | Immunotherapy in colorectal cancer: for the select few or all? | |
| Duarte et al. | Gastric cancer: basic aspects | |
| Marelli et al. | A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer | |
| Dasanu et al. | Immune alterations and emerging immunotherapeutic approaches in lung cancer | |
| Goldberg et al. | Enhancing cancer immunotherapy via activation of innate immunity | |
| JP7148399B2 (ja) | 悪性疾患に対する併用療法 | |
| Saavedra et al. | CIMAvax-EGF: Toward long-term survival of advanced NSCLC | |
| Wahid et al. | An overview of cancer immunotherapeutic strategies | |
| Zibelman et al. | Overview of current treatment options and investigational targeted therapies for locally advanced squamous cell carcinoma of the head and neck | |
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| Lam et al. | Refractory metastatic colorectal cancer: current challenges and future prospects | |
| Rekers et al. | Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives | |
| JP2021534094A (ja) | 未分化リンパ腫キナーゼ阻害剤と組み合わせてｅｇｆ／ｅｇｆｒ経路を抑制するための方法および組成物 | |
| CN109963581A (zh) | 一种il-15蛋白复合物药物组合物及其用途 | |
| AU2020241963A1 (en) | Treatment of cancers using sEphB4-HSA fusion proteins | |
| Hwang et al. | Emerging EGFR-targeted therapy in head and neck cancer: A review | |
| JP2018509423A5 (enExample) | ||
| Bai et al. | Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer | |
| Terrero et al. | Role of immunotherapy in advanced gastroesophageal cancer | |
| CN105407916A (zh) | 二价疫苗组合物以及其用于治疗肿瘤的用途 | |
| Kim et al. | Current status and perspective of immunotherapy in gastrointestinal cancers | |
| Lorenzen et al. | Current status of immunotherapy in gastrointestinal malignancies |